We have updated our privacy policy. If you have any question, contact us at privacy@scicrunch.org. Dismiss and don't show again

Searching across hundreds of databases

Our searching services are busy right now. Your search will reload in five seconds.

Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes.

2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and other aryl hydrocarbon receptor (AhR) ligands suppress 17beta-estradiol (E)-induced responses in the rodent uterus and mammary tumors and in human breast cancer cells. Treatment of ZR-75, T47D, and MCF-7 human breast cancer cells with TCDD induces proteasome-dependent degradation of endogenous estrogen receptor alpha (ERalpha). The proteasome inhibitors MG132, PSI, and PSII inhibit the proteasome-dependent effects induced by TCDD, whereas the protease inhibitors EST, calpain inhibitor II, and chloroquine do not affect this response. ERalpha levels in the mouse uterus and breast cancer cells were significantly lower after cotreatment with E plus TCDD than after treatment with E or TCDD alone, and our results indicate that AhR-mediated inhibition of E-induced transactivation is mainly due to limiting levels of ERalpha in cells cotreated with E plus TCDD. TCDD alone or in combination with E increases formation of ubiquitinated forms of ERalpha, and both coimmunoprecipitation and mammalian two-hybrid assays demonstrate that TCDD induces interaction of the AhR with ERalpha in the presence or absence of E. In contrast, E does not induce AhR-ERalpha interactions. Thus, inhibitory AhR-ERalpha cross talk is linked to a novel pathway for degradation of ERalpha in which TCDD initially induces formation of a nuclear AhR complex which coordinately recruits ERalpha and the proteasome complex, resulting in degradation of both receptors.

Pubmed ID: 12612060 RIS Download

Mesh terms: Animals | Breast Neoplasms | Cycloheximide | Enzyme Inhibitors | Estradiol | Estrogen Receptor alpha | Female | Flavonoids | Humans | MAP Kinase Signaling System | Macromolecular Substances | Mice | Models, Biological | Neoplasm Proteins | Peptide Hydrolases | Polychlorinated Dibenzodioxins | Protease Inhibitors | Proteasome Endopeptidase Complex | Protein Kinase Inhibitors | Protein Processing, Post-Translational | Protein Structure, Tertiary | Protein Synthesis Inhibitors | Receptor Cross-Talk | Receptors, Aryl Hydrocarbon | Receptors, Estrogen | Recombinant Fusion Proteins | Sequence Deletion | Transcriptional Activation | Transfection | Ubiquitin

Research resources used in this publication

None found

Research tools detected in this publication

None found

Data used in this publication

None found

Associated grants

  • Agency: NIEHS NIH HHS, Id: P30 ES009106
  • Agency: NIEHS NIH HHS, Id: R01 ES004176
  • Agency: NIEHS NIH HHS, Id: ES 04176
  • Agency: NIEHS NIH HHS, Id: ES 09106

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

We have not found any resources mentioned in this publication.